Pharmacokinetic Drug Interactions of the New Oral Anticoagulants Revisited

Hillel Halkin^{1

2}

Affiliations

¹ Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
² Tel Aviv University School of Medicine, Tel Aviv, Israel.

Comment

Hillel Halkin. Clin Pharmacol Ther. 2022 Aug.

. 2022 Aug;112(2):208-209.

doi: 10.1002/cpt.2447. Epub 2021 Nov 17.

Hillel Halkin^{1

2}

¹ Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
² Tel Aviv University School of Medicine, Tel Aviv, Israel.

No abstract available

Comment on

Association Between Use of Pharmacokinetic-Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case-Control Study.
Gronich N, Stein N, Muszkat M. Gronich N, et al. Clin Pharmacol Ther. 2021 Dec;110(6):1526-1536. doi: 10.1002/cpt.2369. Epub 2021 Aug 10. Clin Pharmacol Ther. 2021. PMID: 34287842 Free PMC article.

1. van den Heuvel, J.M., Hövels, A.M., Büller, H.R., Mantel-Teeuwisse, A.K., de Boer, A. & Maitland-van der Zee, A.H. NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. Thromb. J. 16, 7 (2018).
1. Vazquez, S.R. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 132, 2230-2239 (2018).
1. Wilfling, D., Hinz, A. & Steinhäuser, J. Big data analysis techniques to address polypharmacy in patients - a scoping review. BMC Fam. Pract. 21, 180 (2020).
1. Rutherford, O.-C.W., Jonasson, C., Ghanima, W., Holst, R. & Halvorsen, S. New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. Open Heart 5, e000931 (2018).
1. Schaefer, J.K. et al. Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication. JAMA Intern. Med. 181, 817-824 (2021).